Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Details

Serval ID
serval:BIB_A7A24C418B5A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Journal
Annals of oncology
Author(s)
Grivas P., Khaki A.R., Wise-Draper T.M., French B., Hennessy C., Hsu C.Y., Shyr Y., Li X., Choueiri T.K., Painter C.A., Peters S., Rini B.I., Thompson M.A., Mishra S., Rivera D.R., Acoba J.D., Abidi M.Z., Bakouny Z., Bashir B., Bekaii-Saab T., Berg S., Bernicker E.H., Bilen M.A., Bindal P., Bishnoi R., Bouganim N., Bowles D.W., Cabal A., Caimi P.F., Chism D.D., Crowell J., Curran C., Desai A., Dixon B., Doroshow D.B., Durbin E.B., Elkrief A., Farmakiotis D., Fazio A., Fecher L.A., Flora D.B., Friese C.R., Fu J., Gadgeel S.M., Galsky M.D., Gill D.M., Glover M.J., Goyal S., Grover P., Gulati S., Gupta S., Halabi S., Halfdanarson T.R., Halmos B., Hausrath D.J., Hawley J.E., Hsu E., Huynh-Le M., Hwang C., Jani C., Jayaraj A., Johnson D.B., Kasi A., Khan H., Koshkin V.S., Kuderer N.M., Kwon D.H., Lammers P.E., Li A., Loaiza-Bonilla A., Low C.A., Lustberg M.B., Lyman G.H., McKay R.R., McNair C., Menon H., Mesa R.A., Mico V., Mundt D., Nagaraj G., Nakasone E.S., Nakayama J., Nizam A., Nock N.L., Park C., Patel J.M., Patel K.G., Peddi P., Pennell N.A., Piper-Vallillo A.J., Puc M., Ravindranathan D., Reeves M.E., Reuben D.Y., Rosenstein L., Rosovsky R.P., Rubinstein S.M., Salazar M., Schmidt A.L., Schwartz G.K., Shah M.R., Shah S.A., Shah C., Shaya J.A., Singh SRK, Smits M., Stockerl-Goldstein K.E., Stover D.G., Streckfuss M., Subbiah S., Tachiki L., Tadesse E., Thakkar A., Tucker M.D., Verma A.K., Vinh D.C., Weiss M., Wu J.T., Wulff-Burchfield E., Xie Z., Yu P.P., Zhang T., Zhou A.Y., Zhu H., Zubiri L., Shah D.P., Warner J.L., Lopes G.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
06/2021
Peer-reviewed
Oui
Volume
32
Number
6
Pages
787-800
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural
Publication Status: ppublish
Abstract
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Patients with active or historical cancer and a laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March and 18 November 2020 were included. The primary outcome was COVID-19 severity measured on an ordinal scale (uncomplicated, hospitalized, admitted to intensive care unit, mechanically ventilated, died within 30 days). Multivariable regression models included demographics, cancer status, anticancer therapy and timing, COVID-19-directed therapies, and laboratory measurements (among hospitalized patients).
A total of 4966 patients were included (median age 66 years, 51% female, 50% non-Hispanic white); 2872 (58%) were hospitalized and 695 (14%) died; 61% had cancer that was present, diagnosed, or treated within the year prior to COVID-19 diagnosis. Older age, male sex, obesity, cardiovascular and pulmonary comorbidities, renal disease, diabetes mellitus, non-Hispanic black race, Hispanic ethnicity, worse Eastern Cooperative Oncology Group performance status, recent cytotoxic chemotherapy, and hematologic malignancy were associated with higher COVID-19 severity. Among hospitalized patients, low or high absolute lymphocyte count; high absolute neutrophil count; low platelet count; abnormal creatinine; troponin; lactate dehydrogenase; and C-reactive protein were associated with higher COVID-19 severity. Patients diagnosed early in the COVID-19 pandemic (January-April 2020) had worse outcomes than those diagnosed later. Specific anticancer therapies (e.g. R-CHOP, platinum combined with etoposide, and DNA methyltransferase inhibitors) were associated with high 30-day all-cause mortality.
Clinical factors (e.g. older age, hematological malignancy, recent chemotherapy) and laboratory measurements were associated with poor outcomes among patients with cancer and COVID-19. Although further studies are needed, caution may be required in utilizing particular anticancer therapies.
NCT04354701.
Keywords
Aged, COVID-19, COVID-19 Testing, Female, Humans, Male, Neoplasms/drug therapy, Neoplasms/epidemiology, Pandemics, SARS-CoV-2, SARS-CoV2, anticancer therapy, cancer, laboratory measurements, neoplasm, outcomes
Pubmed
Open Access
Yes
Create date
30/03/2021 12:03
Last modification date
19/11/2021 7:40
Usage data